Lajos Pusztai, MD, DPhil, discusses the promise of circulating tumor DNA assays in breast cancer.
Lajos Pustzai, MD, DPhil
Advertisement
Articles by Lajos Pustzai, MD, DPhil
Lajos Pusztai, MD, DPhil, discusses the role of circulating tumor DNA as a biomarker of response in patients with high-risk early-stage breast cancer.
Lajos Pustzai, MD, DPhil, professor of Medicine (Medical Oncology), chief of Breast Medical Oncology, co-director, Yale Cancer Center Genetics, Genomics and Epigenetics Program, Yale Cancer Center, discusses how treatment for patients with HER2-positive breast cancer has evolved.
Advertisement
Latest Updated Articles
Dr. Pusztai on the Promise of ctDNA Assays in Breast CancerPublished: December 22nd 2020 | Updated:
Dr. Pusztai on the Role of ctDNA as a Biomarker in Breast CancerPublished: December 15th 2020 | Updated:
Dr. Pusztai on Evolution of Treatment for HER2+ Breast CancerPublished: September 20th 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5